<DOC>
	<DOCNO>NCT00733668</DOCNO>
	<brief_summary>An open-label , non-comparative , multi-centre , phase II prospective trial ass efficacy Quetiapine fumarate augmentation selective serotonin reuptake inhibitor ( SSRIs ) SSRI-resistant major depressive disorder .</brief_summary>
	<brief_title>Efficacy SEROQUEL Selective Serotonin Reuptake Inhibitors ( SSRI ) -Resistant Major Depressive Disorder</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder , Major</mesh_term>
	<mesh_term>Serotonin</mesh_term>
	<mesh_term>Quetiapine Fumarate</mesh_term>
	<mesh_term>Serotonin Uptake Inhibitors</mesh_term>
	<criteria>Inform consent Male female , age 18 65 year . Na√Øve atypical antipsychotic A diagnosis major depressive disorder No use fluvoxamine Patients history bipolar I II disorder Diagnosis psychotic major depression disorder</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2009</verification_date>
	<keyword>consider</keyword>
	<keyword>entry</keyword>
	<keyword />
	<keyword>study</keyword>
	<keyword>SSRI</keyword>
	<keyword>Seroquel</keyword>
	<keyword>Quetiapine</keyword>
	<keyword>fumarate</keyword>
	<keyword>antipsychotic</keyword>
</DOC>